Atlas market file · Equity · United States
YD Bio LtdYDES
- Last close
- 2.295
- Change
- -2.92%
- 96-bar range
- 1.7 – 8.77
- As of
- 7 Aug 2026
YD Bio Ltd is a services-medical laboratories issuer listed as YDES on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
YDES
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 51 weekly closes (-81.64% over the window).
Source rail: Yahoo Finance chart API (YDES). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for YDES. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
YDES public profile
Services-medical laboratories issuer. YD Bio Ltd is connected to current market context, cited company sources and its retained research file.
YD Bio Ltd trades as YDES on NASDAQ. YD Bio Ltd (YDES) has a latest verified close of 2.295, down 2.92%, dated 7 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files YDES under USA Stocks and Science & Biotech Stocks for browsing.
What changed for YD Bio Ltd today
YD Bio Ltd (YDES) reported fiscal 2025 revenues of $596,817, a figure dwarfed by its $16.6M liabilities and $8.3M net loss, raising questions about the sustainability of its clinical trial supply chain services. The company’s balance sheet shows negative equity of $-2.9M and cash reserves of $6.0M, with operating cash flows negative at $-6.6M, indicating a business model reliant on external financing.
Operating as a middleman in pharmaceutical logistics, YDES provides procurement and coordination services but faces a 20% royalty obligation to EG BioMed, creating a structural cash drain. Inventory levels rose $1.8M to $1.9M, suggesting either aggressive stockpiling or stagnant sales. The $1.6M R&D spend and $1.4M capex outlays contrast sharply with its cash burn, highlighting operational tension between growth ambitions and financial reality.
Recent filings (SEC 20-F, 6-K) reveal no major catalysts to reverse declining cash reserves or improve profitability. The 66.7M diluted shares outstanding and $-0.12 EPS underscore a floundering equity narrative. Without a clear path to positive cash flow or debt reduction, YDES remains a speculative micro-cap with thin liquidity and high dilution risk.
Sources & evidence · 9 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
YDES technical readout
Directional bias up. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on YDES
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep YDES research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
YDES FAQ
What is YD Bio Ltd (YDES)?YD Bio Ltd (YDES) has a latest verified close of 2.295, down 2.92%, dated 7 Aug 2026. Use this page to check the price chart, company context, source-backed updates,...
YD Bio Ltd (YDES) has a latest verified close of 2.295, down 2.92%, dated 7 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for YDES?YD Bio Ltd (YDES) has a latest verified close of 2.295, down 2.92%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources, risks and...
YD Bio Ltd (YDES) has a latest verified close of 2.295, down 2.92%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files YDES under USA Stocks and Science & Biotech Stocks for browsing.
How often is the YDES page updated?The YDES public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The YDES public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for YDES?The YDES file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:YDES. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The YDES file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:YDES. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on YDES?Yes. The workstation can open YDES, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open YDES, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this YDES page investment advice?No. The YDES page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The YDES page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →